Drug Profile
RK 023
Alternative Names: Nobiprostolan; RK-023Latest Information Update: 21 Feb 2018
Price :
$50
*
At a glance
- Originator R-Tech Ueno
- Developer Mallinckrodt plc; Sucampo Pharmaceuticals
- Class Fatty acids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Male pattern baldness
- No development reported Hypotrichosis
Most Recent Events
- 13 Feb 2018 Sucampo Pharmaceuticals has been acquired and merged into Mallinckrodt plc
- 04 Nov 2017 No recent reports of development identified for phase-I development in Hypotrichosis(In volunteers) in Japan (Topical, Liquid)
- 07 Dec 2015 R-Tech Ueno has been acquired and merged into Sucampo Pharmaceuticals